Pfizer received approval from the FDA for Xalkori (crizotinib) capsules, the first therapy designed to target anaplastic lymphoma kinase (ALK), for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) that is ALK-positive as detected by Abbott’s molecular diagnostic test. The effectiveness of Xalkori is based on objective response rates (ORR) using a targeted approach in the registration trials. ORR of 50% and 61% were observed in patients with advanced ALK-positive...